Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
13.05
+0.75 (6.10%)
At close: May 22, 2026, 4:00 PM EDT
13.07
+0.02 (0.15%)
After-hours: May 22, 2026, 7:43 PM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
92
Market Cap
177.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIMUX News
- 3 days ago - B. Riley cuts Immunic target, sees ‘compelling entry point’ - TheFly
- 6 days ago - Immunic appoints Michael Bonney as chair - TheFly
- 6 days ago - Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors - PRNewsWire
- 11 days ago - Immunic price target lowered to $19 from $26 at Roth Capital - TheFly
- 12 days ago - Immunic reports Q1 EPS ($1.08), consensus (96c) - TheFly
- 12 days ago - Immunic Quarterly report: Q1 2026 - Filings
- 12 days ago - Immunic Earnings release: Q1 2026 - Filings
- 12 days ago - Immunic Slides: Investor presentation - Filings